AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment

被引：10

作者：

Cho, Shih-Feng ^{[1
]}

Lin, Liang ^{[2
]}

Xing, Lijie ^{[2
]}

Wen, Kenneth ^{[2
]}

Yu, Tengteng ^{[2
]}

Wahl, Joachim ^{[3
]}

Matthes, Katja ^{[3
]}

Munshi, Nikhil ^{[4
]}

Anderson, Kenneth C. ^{[5
]}

Arvedson, Tara ^{[6
]}

Tai, Yu-Tzu ^{[2
]}

机构：

[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dana Farber Canc Inst, Boston, MA USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Amgen Res GmbH, Munich, Germany

[4] Harvard, Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[6] Amgen Res, San Francisco, CA USA

来源：

关键词：

B-cell maturation antigen; BiTE (R) (Bispecific T-cell Engager) molecule; immunotherapy;

D O I：

10.1016/j.clml.2019.09.082

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-081

引用

页码：E54 / E54

页数：1